Advertisement
Canada markets closed

  • S&P/TSX

    22,346.76
    -121.40 (-0.54%)
     

  • S&P 500

    5,307.01
    -14.40 (-0.27%)
     

  • DOW

    39,671.04
    -201.95 (-0.51%)
     

  • CAD/USD

    0.7306
    +0.0000 (+0.01%)
     

  • CRUDE OIL

    77.02
    -0.55 (-0.71%)
     

  • Bitcoin CAD

    95,073.97
    -793.01 (-0.83%)
     

  • CMC Crypto 200

    1,511.49
    -14.93 (-0.98%)
     

  • GOLD FUTURES

    2,370.90
    -22.00 (-0.92%)
     

  • RUSSELL 2000

    2,081.71
    -16.65 (-0.79%)
     

  • 10-Yr Bond

    4.4340
    +0.0200 (+0.45%)
     

  • NASDAQ futures

    18,910.75
    +124.00 (+0.66%)
     

  • VOLATILITY

    12.29
    +0.43 (+3.63%)
     

  • FTSE

    8,370.33
    -46.12 (-0.55%)
     

  • NIKKEI 225

    38,913.48
    +296.38 (+0.77%)
     

  • CAD/EUR

    0.6744
    -0.0001 (-0.01%)
     

Avidity Biosciences to Participate in Upcoming Investor Conference

PR Newswire
·2 min read

SAN DIEGO, May 8, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conference:

(PRNewsfoto/Avidity Biosciences, Inc.)
(PRNewsfoto/Avidity Biosciences, Inc.)

  • BofA Securities 2024 Health Care Conference on May 15 at 8:00 a.m. PT / 11:00 a.m. ET

A live webcast of the event, up-to-date event details and an archived replay will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.

ADVERTISEMENT

About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through internal discovery efforts and key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and X.

Investor Contact:
Geoffrey Grande, CFA
(619) 837-5014
investors@aviditybio.com

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conference-302138982.html

SOURCE Avidity Biosciences, Inc.